Ultrasound Guided Fine-Needle Aspiration Biopsy Proves 100% Accurate in 166 Women

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

A study of 166 women with suspicious mammograms who underwent ultrasound-guided fine-needle aspiration cytology (USFNAC) showed the technique to be 100% accurate in diagnosing cancers, reported Dr. Thomas G. Frazier at the annual

A study of 166 women with suspicious mammograms who underwentultrasound-guided fine-needle aspiration cytology (USFNAC) showedthe technique to be 100% accurate in diagnosing cancers, reportedDr. Thomas G. Frazier at the annual meeting of the American RadiumSociety, held in Paris, France. This number is based on 3-monthfollow-up of the patients, said Dr. Frazier, who is Senior AttendingSurgeon at the Bryn Mawr Hospital in Bryn Mawr, Pennsylvania,

"We found 17 early cancers in our study (none could be felt),"said Dr. Frazier, who is also Clinical Professor of Surgery atthe Medical College of Pennsylvania. "In our study, the costto diagnose each cancer was $4,667 when USFNAC was used. Thiscompares to $52,505 per cancer diagnosed for standard biopsy procedures.That's more than a 91% savings," he commented.

"We looked at the costs of biopsy alone by averaging thecosts of five patients and found that standard biopsies cost about$5,377. This compares to USFNAC, which costs only $478 per procedure,"he said.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content